Home › Compound Library › Vinpocetine

Vinpocetine

Nootropicoral · inferred

Semi-synthetic derivative of vincamine (periwinkle plant alkaloid). Enhances cerebral blood flow, inhibits PDE1, and blocks voltage-gated sodium channels. Rapidly metabolised to apovincaminic acid. High volume of distribution (3.2 L/kg) indicates extensive tissue binding. Take with food to enhance absorption.

Projected serum levels — 10 mg, once daily

Vinpocetine
Vinpocetine modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 10 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.63 mg, trough ≈ 0.023 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Nootropic
Route modeled
Oral
Model confidence
inferred
Half-life
4.8 h
Common dose
10 mg
Suggested maximum
30 mg/day
Reference dose range
5–30 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.012 mg/L at 1 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Vinpocetine CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Vinpocetine AUC by ~0.50x

  • danger
    Efavirenz (Sustiva) + Vinpocetine CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Vinpocetine AUC by ~0.36x

  • danger
    Rifampin + Vinpocetine CYP induction

    Rifampin inducer of CYP3A4 predicted to change Vinpocetine AUC by ~0.36x

  • moderate
    Betamethasone + Vinpocetine CYP induction

    Betamethasone inducer of CYP3A4 predicted to change Vinpocetine AUC by ~0.80x

  • moderate
    Clarithromycin (Biaxin) + Vinpocetine CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Vinpocetine AUC by ~1.29x

  • moderate
    Dasatinib (Sprycel) + Vinpocetine CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Vinpocetine AUC by ~1.25x

Serum checks 63 modeled interaction pairings for vinpocetine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: a randomized, open-label, controlled, multicenter CAVIN trial Zhang W et al. · Clinical Drug Investigation, 2016 DOI

    CAVIN multicentre trial demonstrated that vinpocetine adjunctive therapy improved cerebral blood flow, MMSE scores, NIHSS scores, and quality of life at 90 days in acute cerebral infarction patients.

  2. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions Valikovics A et al. · Ideggyogyaszati Szemle, 2007 DOI

    Twelve weeks of oral vinpocetine treatment significantly increased cerebral blood flow velocity in the middle cerebral artery and improved cognitive function scores in patients with cerebrovascular disease.

  3. Clinical pharmacology of vinpocetine: properties revisited and introduction of a population pharmacokinetic model for its metabolite, apovincaminic acid Pudleiner P et al. · Pharmaceutics, 2023 DOI

    Population pharmacokinetic analysis characterised vinpocetine elimination half-life of ~4.8h and established a two-compartment model for metabolite apovincaminic acid with comprehensive safety review.

3 published studies referenced in the app, each with a plain-language summary.